Skip to main content
SpringerLink
Log in

Is There a Need for “Triple Therapy”? Role of Anticoagulation with Dual Antiplatelet Therapy in Acute Coronary Syndromes (ATLAS Study & TRAP Study)

  • Management of Acute Coronary Syndromes (R Mehran, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

In the past two decades there has been a succession of advances in the development of anticoagulant and antiplatelet therapies to be used in the treatment of ACS. Despite optimal dual antiplatelet therapy, nearly 10-12 % of patients still face a risk of death or myocardial infarction one year following PCI. This large residual risk provides the impetus for the development of more effective strategies. Dual pathway regimens that combine antiplatelets (aspirin and a thienopyridine), along with an anticoagulant such as rivaroxaban may prove to be a therapeutic option in patients with ACS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Baigent C et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337–43.

    Article  PubMed  CAS  Google Scholar 

  2. Fischman DL et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496–501.

    Article  PubMed  CAS  Google Scholar 

  3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39.

    Google Scholar 

  4. Harker LA et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999;21(4):325–35.

    Article  PubMed  CAS  Google Scholar 

  5. Yusuf S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  PubMed  CAS  Google Scholar 

  6. Sabatine MS et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.

    Article  PubMed  CAS  Google Scholar 

  7. Montalescot G et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.

    Article  PubMed  CAS  Google Scholar 

  8. Wiviott SD et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  PubMed  CAS  Google Scholar 

  9. Wallentin L et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2009;361(11):1045–57.

    Article  PubMed  CAS  Google Scholar 

  10. Rothberg MB et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241–50.

    Article  PubMed  CAS  Google Scholar 

  11. Merlini PA et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61–8.

    Article  PubMed  CAS  Google Scholar 

  12. Sconce EA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329–33.

    Article  PubMed  CAS  Google Scholar 

  13. Watson, C.P.a.M., Haematology. 2010; Scion.

  14. Cool DE et al. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. J Biol Chem. 1985;260(25):13666–76.

    PubMed  CAS  Google Scholar 

  15. Gurbel PA et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–13.

    Article  PubMed  Google Scholar 

  16. Brummel-Ziedins K et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost. 2008;6(1):104–10.

    Article  PubMed  CAS  Google Scholar 

  17. Hirsh J. Heparin. New Engl J Med. 1991;324(22):1565–74.

    Article  PubMed  CAS  Google Scholar 

  18. Azar AJ et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol. 1996;27(6):1349–55.

    Article  PubMed  CAS  Google Scholar 

  19. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

  20. Mega JL et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29–38.

    Article  PubMed  CAS  Google Scholar 

  21. Alexander JH et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877–85.

    Article  PubMed  Google Scholar 

  22. • Alexander JH et al. Apixaban with antiplatelet therapy after acute coronary syndrome. New Engl J Med. 2011;365(8):699–708. This trial provides a comparison between apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events.

    Article  PubMed  CAS  Google Scholar 

  23. Sacco RL et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(2):577–617.

    Article  PubMed  Google Scholar 

  24. •• Mega JL et al. Rivaroxaban in patients with a recent acute coronary syndrome. New Engl J Med. 2012;366(1):9–19. In the largest phase II study in the history of medicine the use of low dose rivaroxaban in addition to traditional dual antiplatelet therapy is shown to significantly reduce the incidence of CV death, MI, and stroke in patients with acute coronary syndrome.

    Article  PubMed  CAS  Google Scholar 

  25. Husted S et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5(5):680–8.

    Article  PubMed  Google Scholar 

  26. Cavender MA, B.E., Gibson CM, Wiviott S, Murphy S, Amuchastegui S, Oude Ophuis A , van Hessen M, Mega JL, Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: Findings from ATLAS ACS 2 - TIMI 51 Trial. J Am Coll Cardiol. 2013;61.

  27. Davies MJ. Anatomic features in victims of sudden coronary death. Coronary artery pathology. Circulation. 1992;85(1 Suppl):I19–24.

    PubMed  CAS  Google Scholar 

  28. Becker EM et al. Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. J Thromb Haemost. 2012;10(12):2470–80.

    Article  PubMed  CAS  Google Scholar 

  29. Scirica BM et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380(9850):1317–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

William L. Patrick, Charmaine Patel, Raviteja Guddeti, Aarti Narayan, Michael Maddalen, Shankar Kumar, Kalsang Dolma, Vishnu Vardhan Serla, Maheep Sangha, Aditya Govindavarjhulla, Prashanth Saddala, Priyamvada Singh, and Rim Halaby declare that they have no conflict of interest.

C. Michael Gibson has been a consultant/on advisory boards for AstraZeneca, Baxter Healthcare, Bayer Corporation, Boston Clinical Research Institute, Bristol-Myers Squibb, Cardiovascular Research Foundation, Consensus Medical Communications, CSL Behring, Cytori Therapeutics, Daiichi Sankyo Company, Inc., Eli Lilly and Company, Exeter Group, Ischemix Inc., Janssen Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Merck & Co, Ortho McNeil, Regado Biosciences, Sanofi-Aventis, St. Jude Medical, and The Medicines Company. He has received grant/research support from Angel Medical Corporation, Atrium Medical Systems, Bayer Corporation, Genentech, Inc., Ikaria, Inc., Janssen Pharmaceuticals, Johnson & Johnson Corporation, Lantheus Medical Imaging, Merck & Co., Portola Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Stealth Peptides, Inc., St. Jude Medical, Volcano Corp., and Walk Vascular. He receives royalties as a contributor from UpToDate in Cardiovascular Medicine and Pocket Medicine. He participates in peer to peer communications with Daiichi Sankyo Company, Eli Lilly and Company, and The Medicines Company. His past research has been supported by Abbott and Schering-Plough Corporation. His has received past royalties as a contributor to Pocket Medicine.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. PERFUSE Study Group, Beth Israel Deaconess Medical Center, Cardiovascular Division, Department of Medicine, Harvard Medical School, 185 Pilgrim Road, Farr 319, Boston, MA, 02215, USA

    William L. Patrick, Charmaine Patel, Raviteja Guddeti, Aarti Narayan, Michael Maddaleni, Shankar Kumar, Kalsang Dolma, Vishnu Vardhan Serla, Maheep Sangha, Aditya Govindavarjhulla, Prashanth Saddala, Priyamvada Singh, Rim Halaby & C. Michael Gibson

Authors
  1. William L. Patrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charmaine Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raviteja Guddeti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aarti Narayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Maddaleni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shankar Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kalsang Dolma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vishnu Vardhan Serla
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maheep Sangha
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aditya Govindavarjhulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Prashanth Saddala
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Priyamvada Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rim Halaby
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C. Michael Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Michael Gibson.

Additional information

This article is part of the Topical Collection on Management of Acute Coronary Syndromes

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patrick, W.L., Patel, C., Guddeti, R. et al. Is There a Need for “Triple Therapy”? Role of Anticoagulation with Dual Antiplatelet Therapy in Acute Coronary Syndromes (ATLAS Study & TRAP Study). Curr Cardiol Rep 15, 411 (2013). https://doi.org/10.1007/s11886-013-0411-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-013-0411-1

Keywords

Search

Navigation